Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

DOI Full Paper Access

309

Citations

23

References

2019

Year

Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Dávila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin,

Clinical Cancer Research

Abstract

Rova-T is the first targeted agent in SCLC to use DLL3, a novel biomarker. However, results demonstrate modest clinical activity in 3L+ SCLC, with associated toxicities.

References

	Year	Citations

Page 1